BiomeBank is developing microbial therapies using its proprietary Consortiome™ platform, which creates an artificial human gut microbial community to restore gut microbial ecology. This approach addresses the decline in gut bacterial diversity linked to chronic diseases by enabling the development of targeted therapies at a lower cost than traditional microbial products.
Funding
$32.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ECFounders
Product
Problem
Modern lifestyles and environments are causing a decline in gut bacterial diversity, which is associated with the rise of numerous chronic diseases. Current therapies for these diseases often have low remission rates and serious side effects. There is an urgent need for effective new therapies without these drawbacks.
Solution
BiomeBank is a clinical-stage biotechnology company developing novel, cultured microbial therapies to treat and prevent disease by restoring gut microbial ecology. The company's Consortiome™ platform enables the co-culturing of an artificial human gut microbial community in a bioreactor. This platform facilitates the development of bespoke therapies with targeted functions to treat disease at a lower cost than traditional microbial products. BiomeBank's donor-derived microbiome therapy was the first regulator-approved microbial therapy in the world and is currently supplied to physicians to treat patients with _Clostridioides difficile_ infection.
Target Audience
The primary customers are clinicians seeking therapies to treat diseases associated with a decline in gut bacterial diversity, as well as patients suffering from chronic bowel disorders.
Features
- Consortiome™ platform: a breakthrough co-culturing platform that generates an artificial human gut microbial community in a bioreactor
- Rationally designed consortia containing more than 90% of the known gene families in a healthy person’s microbiome
- Identification of disease causation using real-world, human data from existing therapies
- Selection of candidate strains from a leading culture collection
- Engineering of ecologically diverse consortia of microbes carrying specific mechanisms of action
- Therapies target diseases such as ulcerative colitis and _Clostridioides difficile_ infection